AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma

被引:0
作者
Onur Yaprak
Murat Akyildiz
Murat Dayangac
Baha Tolga Demirbas
Necdet Guler
Gulen Bulbul Dogusoy
Yildiray Yuzer
Yaman Tokat
机构
[1] OrganTransplantationCenter,SisliFlorenceNightingaleHospital
关键词
liver transplantation; hepatocellular carcinoma; alpha-fetoprotein;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
BACKGROUND: In liver transplantation or resection for hepatocellular carcinoma (HCC), patient selection depends on morphological features. In patients with HCC, we performed a clinicopathological analysis of risk factors that affected survival after liver transplantation. METHODS: In 389 liver transplantations performed from 2004 to 2010, 102 were for HCC patients. Data were collected retrospectively from the Organ Transplantation Center Database. Variables were as follows: age, gender, preoperative alpha-fetoprotein (AFP) levels, Child-Pugh and MELD scores, prognostic staging criteria (Milan and UCSF), etiology, number of tumors, the largest tumor size, total tumor size, multifocality, intrahepatic portal vein tumor thrombosis, bilobarity, and histological differentiation. RESULTS: One hundred and two patients were evaluated. The 5-year overall survival rate was 56.5%. According to the UCSF criteria, 63% of the patients were within and 37% were beyond UCSF (P=0.03). Ten patients were excluded (one with fibrolamellary HCC and 9 because of early postoperative death without HCC recurrence), and 92 patients were assessed. The mean age of the patients was 56.5±6.9 years. Sixty-two patients underwent living donor liver transplantations. The mean follow-up time was 29.4±22.6 months. Fifteen patients (16.3%) died in the follow-up period due to HCC recurrence. Univariate analysis showed that AFP level, intrahepatic portal vein tumor thrombosis, histologic differentiation and UCSF criteria were significant factors related to survival and tumor recurrence. The 5-year estimated overall survival rate was 62.2% in allpatients. According to the UCSF criteria, and the 5-year overall survival rate was 66.7% within and 52.7% beyond the criteria (P=0.04). Multivariate analysis showed that AFP level and poor differentiation were independent factors. CONCLUSIONS: For proper patient selection in liver trans- plantation for HCC, prognostic criteria related to tumor biology (especially AFP level and histological differentiation) should be considered. Poor differentiation and higher AFP levels are indicators of poor prognosis after liver transplantation.
引用
收藏
页码:256 / 261
页数:6
相关论文
共 19 条
[1]   Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion [J].
DuBay, Derek ;
Sandroussi, Charbel ;
Sandhu, Lakhbir ;
Cleary, Sean ;
Guba, Markus ;
Cattral, Mark S. ;
McGilvray, Ian ;
Ghanekar, Anand ;
Selzner, Markus ;
Greig, Paul D. ;
Grant, David R. .
ANNALS OF SURGERY, 2011, 253 (01) :166-172
[2]   Report of a National conference on Liver Allocation in Patients with Hepatocellular Carcinoma in the United States [J].
Pomfret, Elizabeth A. ;
Washburn, Kenneth ;
Wald, Christoph ;
Nalesnik, Michael A. ;
Douglas, David ;
Russo, Mark ;
Roberts, John ;
Reich, David J. ;
Schwartz, Myron E. ;
Mieles, Luis ;
Lee, Fred T. ;
Florman, Sander ;
Yao, Francis ;
Harper, Ann ;
Edwards, Erick ;
Freeman, Richard ;
Lake, John .
LIVER TRANSPLANTATION, 2010, 16 (03) :262-278
[3]  
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics[J] . Shariff,Cox,Gomaa,Khan,Gedroyc,Taylor-Robinson.Expert Review of Gastroenterology & Hepatology . 2009 (4)
[4]  
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J] . Vincenzo Mazzaferro,Josep M Llovet,Rosalba Miceli,Sherrie Bhoori,Marcello Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron E Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K Burroughs,Roberto Troisi,Massimo Rossi,Giorgio E Gerunda,Jan Lerut,Jac
[5]   Impact of Des-Gamma-Carboxy Prothrombin and Tumor Size on the Recurrence of Hepatocellular Carcinoma After Living Donor Liver Transplantation [J].
Taketomi, Akinobu ;
Sanefuji, Kensaku ;
Soejima, Yuji ;
Yoshizumi, Tomoharu ;
Uhciyama, Hideaki ;
Ikegami, Toru ;
Harada, Noboru ;
Yamashita, Yoichi ;
Sugimachi, Keishi ;
Kayashima, Hiroto ;
Iguchi, Tomohiro ;
Maehara, Yoshihko .
TRANSPLANTATION, 2009, 87 (04) :531-537
[6]   Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center [J].
Lee, Sung-Gyu ;
Hwang, Shin ;
Moon, Deok-Bog ;
Ahn, Chul-Soo ;
Kim, Ki-Hun ;
Sung, Kyu-Bo ;
Ko, Gi-Young ;
Park, Kwang-Min ;
Ha, Tae-Yong ;
Song, Gi-Won .
LIVER TRANSPLANTATION, 2008, 14 (07) :935-945
[7]   Diagnosis and treatment of hepatocellular carcinoma [J].
El-Serag, Hashem B. ;
Marrero, Jorge A. ;
Rudolph, Lenhard ;
Reddy, K. Rajender .
GASTROENTEROLOGY, 2008, 134 (06) :1752-1763
[8]  
Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences[J] . Shu-Sen Zheng,Xiao Xu,Jian Wu,Jun Chen,Wei-Lin Wang,Min Zhang,Ting-Bo Liang,Li-Ming Wu.Transplantation . 2008 (12)
[9]  
Extending indication: Role of living donor liver transplantation for hepatocellular carcinoma[J] . Satoru Todo,Hiroyuki Furukawa,Mitsuhiro Tada.Liver Transpl . 2007 (S2)
[10]  
Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Special Reference to a Preoperative Des-Gamma-Carboxy Prothrombin Value[J] . M. Shimada,Y. Yonemura,H. Ijichi,N. Harada,S. Shiotani,M. Ninomiya,T. Terashi,T. Yoshizumi,Y. Soejima,Y. Maehara.Transplantation Proceedings . 2005 (2)